menu
    • menu
    [{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"},{"orgOrder":0,"company":"Medicus Pharma","sponsor":"Maxim Group LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Doxorubicin Hydrochloride","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Medicus Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Medicus Pharma \/ Maxim Group LLC","highestDevelopmentStatusID":"8","companyTruncated":"Medicus Pharma \/ Maxim Group LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Medicus Pharma

    Menu

    Medicus Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Medicus Pharma

                            Canada arrow
                            PharmaVenue
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Medicus Pharma Raises $4.0M Through Initial Public Offering in the United States

                            Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.

                            Brand Name : D-MNA

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 19, 2024

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Medicus Pharma

                            Canada arrow
                            PharmaVenue
                            Not Confirmed

                            Medicus Pharma

                            Canada arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Medicus Pharma Raises $4.0M in U.S. Initial Public Offering for Pipeline Growth

                            Details : The Company intends to use the proceeds to fund its Phase 2 proof of concept trial for basal cell carcinoma using its doxorubicin tip loaded dissolvable microarray needle skinpatch, D-MNA.

                            Brand Name : D-MNA

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Maxim Group LLC

                            Deal Size : $4.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth